Cover Image
市場調查報告書

被套細胞淋巴瘤:開發平台分析

Mantle Cell Lymphoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229748
出版日期 內容資訊 英文 426 Pages
訂單完成後即時交付
價格
Back to Top
被套細胞淋巴瘤:開發平台分析 Mantle Cell Lymphoma - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 426 Pages
簡介

被套細胞淋巴瘤是濾泡周圍的套區(mantle zone) 之前驅B細胞亞族群所產生的淋巴增生性疾病。這個疾病主要患者多在60∼65歲,男性居多。一開始的症狀有伴隨淋巴結肥大的頸部、腋下、鼠蹊部的無痛腫脹,通常作用在一個以上的淋巴結群。其他也會影響骨髓及腸道、胃、肝臟、脾臟等。其他症狀有食慾衰退和疲勞感(倦怠感)等。也有患者產生盜汗和高燒、體重減輕等。淋巴腫如果作用到腸胃就會引起下痢及嘔吐。

本報告提供全球各國的被套細胞淋巴瘤治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

被套細胞淋巴瘤(MCL)概要

治療藥的開發

  • 被套細胞淋巴瘤開發中產品:概要
  • 被套細胞淋巴瘤開發中產品:比較分析

各企業正在開發的被套細胞淋巴瘤治療藥

大學/研究機關研究中的被套細胞淋巴瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

被套細胞淋巴瘤治療藥:開發中的產品一覽(各企業)

被套細胞淋巴瘤治療藥:研究中的產品一覽(大學/研究機關別)

被套細胞淋巴瘤開發治療藥的企業

  • AB Science SA
  • AbbVie Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.
  • Affimed Therapeutics AG
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellular Biomedicine Group, Inc.
  • Eisai
  • EpiZyme, Inc.
  • Fate Therapeutics, Inc.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Hutchison MediPharma Limited
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Inflection Biosciences Limited
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Karyopharm Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Les Laboratoires Servier SAS
  • LFB S.A.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • MorphoSys AG
  • Nordic Nanovector ASA
  • Novartis AG
  • Onconova Therapeutics, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Pharmacyclics, Inc.
  • Portola Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Selvita S.A.
  • Sorrento Therapeutics, Inc.
  • Stemline Therapeutics, Inc.
  • 武田藥品工業
  • TG Therapeutics, Inc.

被套細胞淋巴瘤:治療藥的評估

  • 單劑治療藥的情況
  • 組合產品
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (INCB-039110 + INCB-040093)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 13197
  • AB-8779
  • abexinostat hydrochloride
  • acalabrutinib
  • acalisib
  • ACY-241
  • ACY-775
  • AFM-11
  • agatolimod sodium
  • alisertib
  • AMG-319
  • ASN-002
  • AT-7519
  • avicin d
  • bendamustine hydrochloride
  • Betalutin
  • BGB-3111
  • BLyS-gel
  • BMS-986016
  • buparlisib hydrochloride
  • carfilzomib
  • CBM-C19.1
  • CBM-C20.1
  • CC-122
  • Cellular Immunotherapy for Oncology
  • Cellular Immunotherapy to Target CD19 for Oncology
  • Cellular Immunotherapy to Target ROR1 for Oncology
  • cerdulatinib
  • copanlisib hydrochloride
  • daratumumab
  • denintuzumab mafodotin
  • E-7449
  • entospletinib
  • epratuzumab
  • EPZ-015666
  • FT-1050
  • HMPL-523
  • IBL-301
  • ibrutinib
  • idelalisib
  • IGN-002
  • IMGN-529
  • IMMU-114
  • INA-01
  • INCB-40093
  • inebilizumab
  • inebilizumab + MEDI-0680
  • inebilizumab + rituximab
  • itacitinib adipate
  • ixazomib citrate
  • JCAR-014
  • JCAR-015
  • JCAR-017
  • JNJ-64052781
  • KTEC-19
  • LAM-002A
  • lenalidomide
  • Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies
  • Monoclonal Antibody Conjugate to Target CD45 for Oncology
  • MOR-208
  • ON-123300
  • ONC-201
  • OSU-2S
  • pembrolizumab
  • polatuzumab vedotin
  • ribociclib
  • S-055746
  • SEL-120
  • SEL-12034
  • SEL-24B489
  • selinexor
  • SGN-CD70A
  • SL-101
  • TAK-659
  • temsirolimus
  • TGR-1202
  • tisagenlecleucel-T
  • tretinoin
  • ublituximab
  • venetoclax
  • vorinostat

被套細胞淋巴瘤治療藥:開發中產品的最新趨勢

被套細胞淋巴瘤治療藥:開發暫停的產品

被套細胞淋巴瘤治療藥:開發中止的產品

被套細胞淋巴瘤相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8348IDB

Summary

Global Markets Direct's, 'Mantle Cell Lymphoma - Pipeline Review, H2 2016', provides an overview of the Mantle Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
  • The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects
  • The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mantle Cell Lymphoma Overview
  • Therapeutics Development
    • Pipeline Products for Mantle Cell Lymphoma - Overview
    • Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis
  • Mantle Cell Lymphoma - Therapeutics under Development by Companies
  • Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
  • Mantle Cell Lymphoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Mantle Cell Lymphoma - Products under Development by Companies
  • Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes
  • Mantle Cell Lymphoma - Companies Involved in Therapeutics Development
    • AB Science SA
    • AbbVie Inc
    • Acetylon Pharmaceuticals, Inc.
    • Actinium Pharmaceuticals, Inc.
    • Affimed GmbH
    • Amgen Inc.
    • Asana BioSciences, LLC
    • Astellas Pharma Inc.
    • Astex Pharmaceuticals, Inc.
    • Bayer AG
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Cellular Biomedicine Group, Inc.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • EpiZyme, Inc.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Hutchison MediPharma Limited
    • ImmunoGen, Inc.
    • Immunomedics, Inc.
    • Incyte Corporation
    • Inflection Biosciences Limited
    • Johnson & Johnson
    • Juno Therapeutics Inc.
    • Karyopharm Therapeutics, Inc.
    • Kite Pharma, Inc.
    • LFB S.A.
    • MacroGenics, Inc.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • MorphoSys AG
    • Nordic Nanovector ASA
    • Novartis AG
    • Onconova Therapeutics, Inc.
    • Oncternal Therapeutics, Inc.
    • Patrys Limited
    • Pharmacyclics, Inc.
    • Portola Pharmaceuticals, Inc.
    • Seattle Genetics, Inc.
    • Selvita S.A.
    • Stemline Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • TG Therapeutics, Inc.
    • Vivolux AB
  • Mantle Cell Lymphoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (INCB-039110 + INCB-040093) - Drug Profile
    • 13197 - Drug Profile
    • AB-8779 - Drug Profile
    • abexinostat hydrochloride - Drug Profile
    • acalabrutinib - Drug Profile
    • ACY-241 - Drug Profile
    • ACY-775 - Drug Profile
    • AFM-11 - Drug Profile
    • alisertib - Drug Profile
    • AMG-319 - Drug Profile
    • ASN-002 - Drug Profile
    • AT-7519 - Drug Profile
    • avicin d - Drug Profile
    • BC-8Y90 - Drug Profile
    • bendamustine hydrochloride - Drug Profile
    • Betalutin - Drug Profile
    • BGB-3111 - Drug Profile
    • BLyS-gel - Drug Profile
    • BMS-986016 - Drug Profile
    • buparlisib hydrochloride - Drug Profile
    • carfilzomib - Drug Profile
    • CBM-C19.1 - Drug Profile
    • CBM-C20.1 - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
    • cerdulatinib - Drug Profile
    • copanlisib hydrochloride - Drug Profile
    • daratumumab - Drug Profile
    • denintuzumab mafodotin - Drug Profile
    • durvalumab - Drug Profile
    • E-7449 - Drug Profile
    • entospletinib - Drug Profile
    • epratuzumab - Drug Profile
    • EPZ-015666 - Drug Profile
    • HMPL-523 - Drug Profile
    • IBL-301 - Drug Profile
    • ibrutinib - Drug Profile
    • IGN-002 - Drug Profile
    • IMGN-529 - Drug Profile
    • IMMU-114 - Drug Profile
    • INA-01 - Drug Profile
    • INCB-40093 - Drug Profile
    • INCB-50465 - Drug Profile
    • inebilizumab - Drug Profile
    • inebilizumab + MEDI-0680 - Drug Profile
    • Iomab-B - Drug Profile
    • itacitinib adipate - Drug Profile
    • ixazomib citrate - Drug Profile
    • JCAR-014 - Drug Profile
    • JCAR-015 - Drug Profile
    • JCAR-017 - Drug Profile
    • JNJ-64052781 - Drug Profile
    • KTEC-19 - Drug Profile
    • LAM-002A - Drug Profile
    • M-7583 - Drug Profile
    • Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile
    • Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile
    • MOR-208 - Drug Profile
    • ON-123300 - Drug Profile
    • ONC-201 - Drug Profile
    • OSU-2S - Drug Profile
    • PATLM-1 - Drug Profile
    • PCAR-019 - Drug Profile
    • pembrolizumab - Drug Profile
    • ramucirumab - Drug Profile
    • ribociclib succinate - Drug Profile
    • S-055746 - Drug Profile
    • sapanisertib - Drug Profile
    • SEL-120 - Drug Profile
    • SEL-12034 - Drug Profile
    • SEL-24B489 - Drug Profile
    • selinexor - Drug Profile
    • SGN-CD70A - Drug Profile
    • SL-101 - Drug Profile
    • spebrutinib besylate - Drug Profile
    • TAK-659 - Drug Profile
    • TGR-1202 - Drug Profile
    • tisagenlecleucel-T - Drug Profile
    • tretinoin - Drug Profile
    • ublituximab - Drug Profile
    • UC-961 - Drug Profile
    • venetoclax - Drug Profile
    • VLX-1570 - Drug Profile
    • vorinostat - Drug Profile
  • Mantle Cell Lymphoma - Dormant Projects
  • Mantle Cell Lymphoma - Discontinued Products
  • Mantle Cell Lymphoma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mantle Cell Lymphoma, H2 2016
  • Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Mantle Cell Lymphoma - Pipeline by AB Science SA, H2 2016
  • Mantle Cell Lymphoma - Pipeline by AbbVie Inc, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Affimed GmbH , H2 2016
  • Mantle Cell Lymphoma - Pipeline by Amgen Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Asana BioSciences, LLC, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Bayer AG, H2 2016
  • Mantle Cell Lymphoma - Pipeline by BeiGene, Ltd., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H2 2016
  • Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Kite Pharma, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by LFB S.A., H2 2016
  • Mantle Cell Lymphoma - Pipeline by MacroGenics, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Merck KGaA, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Novartis AG, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Patrys Limited, H2 2016
  • Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Selvita S.A., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2016
  • Mantle Cell Lymphoma - Pipeline by Vivolux AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Mantle Cell Lymphoma - Dormant Projects, H2 2016
  • Mantle Cell Lymphoma - Dormant Projects (Contd..1), H2 2016
  • Mantle Cell Lymphoma - Dormant Projects (Contd..2), H2 2016
  • Mantle Cell Lymphoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Mantle Cell Lymphoma, H2 2016
  • Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top